First Breast Cancer Patients in Europe to be Treated With Revolutionary Therapy System

VEENENDAAL, The Netherlands, March 4, 2010 - Today the first patients in Europe are to receive treatment for breast
cancer using a revolutionary system called AccuBoost. The Italian hospital
where the patients are being treated is using the technology to pinpoint the
tumour bed and treat it whilst still protecting the patient's healthy
surrounding tissue and organs. This is made possible by the system combining
real-time mammographic image guidance and non-invasive use of a radiotherapy
technique called brachytherapy.

Professor Roberto Orecchia; Director of the Division of Radiotherapy, is
leading the use of the new system at the Istituto Europeo di Oncologia in
Milan and explained: 'When the patient is treated with AccuBoost, the image
is seen in real-time, guaranteeing radiotherapy that is extremely precise in
its targeting of the tumour bed. This is a very innovative procedure because
for the first time mammography images can be used to guide the radiotherapy
treatment in such an extremely precise and adaptive manner. There is also a
time benefit, so this year, we will be able to treat 50 percent of patients
more quickly and efficiently than before, reducing treatment time from six
weeks to three weeks.'

The Istituto Europeo di Oncologia is the first hospital in Europe to use
AccuBoost, which was certified for use in Europe just six weeks ago. The
technology was developed by Nucletron and ART, two companies specialising in
advancing radiation oncology by developing state-of-the-art equipment for
high precision brachytherapy. More information is available at
www.treatwhatyousee.com

About brachytherapy

Brachytherapy is a high-precision radiation therapy, in which the
radiation source used to kill cancer cells and shrink tumours is placed in or
close to the tumour itself. The precision brachytherapy approach allows a
physician to concentrate a high dose of radiation in a small area, minimising
damage to nearby, healthy body tissue and organs, over a shorter treatment
period.

About Nucletron

Nucletron is a knowledge-based leader in Radiation Oncology, working with
clinical teams to realise innovative solutions that improve patient care.
Nucletron strives to offer the best possible choice of radiation modalities
through integrated products, software and services. For more information,
visit www.nucletron.com/.

About ART

ART is a women's health company dedicated to the advancement of partial
breast irradiation with the goal of reducing the cancer recurrence rate and
minimizing radiation related complications. For more information, visit
www.accuboost.com/.

For more information contact:

Mark van Braak at Nucletron, Veenendaal on +31-318-557-255 or email
mark.vanbraak@nucletron.com. Philip Sheldon at Red Door Communications,
London on +44(0)208-392-8093 or email psheldon@rdcomms.com

Mark van Braak at Nucletron, Veenendaal on +31-318-557-255 or email
mark.vanbraak at nucletron.com. Philip Sheldon at Red Door Communications,
London on +44(0)208-392-8093 or email psheldon at rdcomms.com